Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, rando (Q57579457)

From Wikidata

Jump to navigation Jump to search

scientific article published on 28 September 2014

Language	Label	Description	Also known as
English	Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, rando	scientific article published on 28 September 2014

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273342%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273342%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

metastatic breast cancer

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273342%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273342%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273342%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Michelino De Laurentiis

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273342%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Joseph Gligorov

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273342%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

author name string

Gunter von Minckwitz

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273342%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Eduard Vrdoljak

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273342%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Norbert Marschner

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273342%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Christoph Zielinski

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273342%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Cristian Villanueva

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273342%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Gilles Romieu

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273342%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

István Lang

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273342%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Corinne Veyret

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273342%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Sabine de Ducla

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273342%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Ulrich Freudensprung

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273342%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Stefanie Srock

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273342%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

publication date

28 September 2014

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273342%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273342%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273342%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273342%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1269-1278

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273342%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic br

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

VEGF inhibition: insights from preclinical and clinical studies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival outcomes of bevacizumab beyond progression in metastatic colorectal cancer patients treated in US community oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Issues in using progression-free survival when evaluating oncology products

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A note on quantifying follow-up in studies of failure time

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Final overall survival results and effect of prolonged (≥ 1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Cancer: The nuances of therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatme

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Can bevacizumab prolong survival for glioblastoma patients through multiple lines of therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(14)70439-5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273342%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25273342%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57579457&oldid=1970342815"